Mountain Crest Acquisition Corp. V (MCAG) remains focused on consummating its initial business combination, having shifted target focus from the terminated AUM Biosciences deal to a new proposed transaction with Korea-based CUBEBIO Co., Ltd. Despite limited liquidity and Nasdaq listing transitions, the management team leverages its sector-specific expertise and regional networks targeting undervalued companies in North America and Asia Pacific (excluding China). The company faces critical execution risks related to geopolitical instability, tight funding, and regulatory compliance deadlines but aims to unlock value through its disciplined acquisition strategy. Upcoming milestones center on closing the CUBEBIO deal and navigating shareholder approvals under extended timelines.